The Quantellect read.As of Nov 19, 2026, 8 active firms cover Rxsight Inc: 1 rate it Buy or better, 6 sit at Neutral, and 1 rate it Sell or worse, a neutral consensus. Targets range widely, $5.50 to $11.00 (about 2.0x), a sign of real disagreement on valuation. The average target of $8.07 sits 61% above the current $5.01. Sentiment has drifted a little more constructive lately, with Sell ratings easing from 2 to 1 over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.14 next quarter toward $-0.67 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS8 active firms
Neutral
Strong Buy00%
Buy113%
Neutral675%
Sell113%
Strong Sell00%
Based on 8 active firms as of Nov 19, 2026 (365-day activity window).
12-MONTH PRICE TARGET
$8.07
+61.2% upside
Average target across 8 active firms as of Nov 19, 2026 vs $5.01 current
Highest Target$11.00
Average Target$8.07
Lowest Target$5.50
Detailed analyst forecasts for RXST
Showing 1–8 of 8 named analysts shown · 8 active firms in the rating projection
As of Nov 19, 2026, 1 of 8 active firms rate RXST a Buy (6 Neutral, 1 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
RXST EPS & revenue forecast
EPS · NEXT QUARTER
$-0.14
Range $-0.14 – $-0.13 · 2 analysts · -29% YoY
Next period, 2 analysts expect Rxsight Inc to earn $-0.14 a share (range $-0.14 – $-0.13), versus $-0.19 a year earlier. Full-year consensus is $-0.13, growing to $-0.67 the year after.
REVENUE · NEXT QUARTER
$29.6M
Range $26.3M – $32.6M · 2 analysts · -4% YoY
Revenue is expected to reach $29.6M (range $26.3M – $32.6M), -4.1% year-over-year. Full-year consensus is $146.8M, rising to $115.7M next year.
Top analysts covering Rxsight Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on RXST.
#1
Ryan Zimmerman
BTIG · Rank #212
Neutral
No targeton RXST
Overall win rate
37%
+ Follow
#2
David Saxon
Needham · Rank #426
Buy
$11.00+119.8% to target
Overall win rate
32%
+ Follow
#3
LB
Larry Biegelsen
Wells Fargo
Neutral
$9.00+79.8% to target
Coverage
—
+ Follow
#4
YL
Young Li
Jefferies
Neutral
$5.75+14.9% to target
Coverage
—
+ Follow
#5
Adam Maeder
Piper Sandler
Neutral
$10.00+99.8% to target
Coverage
—
+ Follow
RXST stock forecast FAQ
What is RXST's average 12-month price target?+
The 8 active firms with a live target average $8.07 for Rxsight Inc over the next 12 months, ranging from a $11.00 high to a $5.50 low, as of Nov 19, 2026.
Is RXST stock a Buy, Sell or Neutral right now?+
The current consensus is Neutral. Of the 8 active firms as of Nov 19, 2026, 1 rate it Buy or Strong Buy, 6 rate it Neutral, and 1 rate it Sell or Strong Sell.
What are the highest and lowest price targets for RXST?+
The Street-high target is $11.00 (Needham), and the Street-low is $5.50 (B of A Securities). The average of all 8 active-firm targets is $8.07.
How many active Wall Street firms cover RXST?+
8 active firms have a recognized rating on Rxsight Inc as of Nov 19, 2026, and 8 active firms carry a live 12-month price target.
Who is the most accurate analyst covering RXST?+
Among analysts who currently cover RXST, Ryan Zimmerman of BTIG has the strongest overall Quantellect track record (Rank #212). Their current call is Neutral.
What is Rxsight Inc's projected EPS for next quarter?+
The consensus estimate is $-0.14 per share (range $-0.14 – $-0.13) across 2 analysts. Full-year EPS is projected at $-0.13, rising to $-0.67 the following year.
How much revenue is Rxsight Inc expected to report next quarter?+
Consensus revenue is $29.6M (range $26.3M – $32.6M). Full-year revenue is projected at $146.8M, growing to $115.7M next year.
Have analysts been upgrading or downgrading RXST lately?+
As of Nov 19, 2026, 1 of 8 active firms rate RXST a Buy (6 Neutral, 1 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their RXST calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.